NKGen Biotech Inc. · OTC:NKGN

NKGen Biotech — Investor Presentation (September 2024)

39 slides from NKGen Biotech's investor presentation, September 2024

  1. Slide 1: Maximizing Immune Integrity

    Maximizing Immune Integrity NK Cell Therapy for Neurodegenerative Disease September 2024

  2. Slide 2: Disclaimer: Forward-Looking Statements

    Disclaimer Forward-Looking Statements This Presentation may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. NKGen Biotech, Inc.'s ("NKGen" or "the Company") forward-looking statements inc

  3. Slide 3: Disclaimer: Forward-Looking Statements

    Disclaimer Forward-Looking Statements Important factors that may affect actual results or outcomes include, among others, the risk that regulatory approvals for the Company’s product development are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect NKGe

  4. Slide 4: Corporate Information

    Corporate Information NKGen was founded in 2017 – Investment to date is 54 Full-time Employees + 4 Part-time $130M 35 GMP 9 Clinical Lab • NKGen merged with Graf Acquisition Corp. IV in October 2023 and listed on NASDAQ under the ticker NKGN 2 Clinical Operations • Prior investments funded purchase

  5. Slide 5: Executive and Leadership Team

    Executive and Leadership Team Sangwoo Park* Paul Y. Song, MD* James Graf Yong Man Kim, PhD Founder & Director Chairman & CEO Chief Financial Officer (Interim) Chief Scientific Officer Founder of NKMAX [Former Korean Parent Company] Ryan Park, CFA Irene Chang Yoonmi Kang Denise Chua, MBA, CLS, SVP, T

  6. Slide 6: Natural Killer Cells

    Natural Killer Cells Innate Lymphoid Cells: • 5-20% of circulating lymphocytes (CD3- CD56+) Can Distinguish Healthy Cells (self) from Dangerous Cells (non-self): • Ability to identify and eliminate “dangerous” cells • Mediate antibody-dependent cellular cytotoxicity (“ADCC”) • Immune regulatory capa

  7. Slide 7: NKGen's Differentiated CMC Manufacturing Platform

    NKGen's Differentiated CMC1 Manufacturing Platform Cryopreserved non-genetically modified Autologous and Allogeneic products Cryopreservation process that can maintain high viability, cytotoxicity, and activating receptor expression Expansion capability demonstrates the potential to produce commerci

  8. Slide 8: State-Of-The-Art GMP Manufacturing Facility

    State-Of-The-Art GMP1 Manufacturing Facility Licensed cell therapy manufacturing facility • 25,000 sq ft facility (12,000 sq ft for GMP) completed in 2019 • CLIA2 certified and CAP3 accredited clinical laboratory • Facility owned and operated by NKGen Biotech 1 GMP = Good Manufacturing Practice, a s

  9. Slide 9: NKGen's IP Protected Manufacturing Process Results in Super NK Cells

    NKGen’s IP Protected Manufacturing (CMC) Process Results in Super NK Cells NKGen can expand NK cells from any donor! Expansion Fold Expansion Fold 6000 6000 (8 Healthy Donors) (11 Cancer Patients) NKGen can increase receptor expression! 5060 5022 4000 4000 3915 FOLD (X) FOLD (X) Expansion 3140 100 N

  10. Slide 10: Autologous Next Gen Manufacturing

    Autologous Next Gen Manufacturing NKGen “Off-the-Shelf Autologous” SNK Cell1 Therapy Superior Cell Our Expansion and Cryoprocess Activation preserves cell features Auto-SNK No Lymphodepletion 1 2 3 5 4 5 Collect Isolate Activate & Expand Cryopreserve Deliver to Clinic Thaw and Administer Leukapheres

  11. Slide 11: SNK01 – Mechanism of Action in Neurodegenerative Disease

    SNK01 – Mechanism of Action in Neurodegenerative Disease 11

  12. Slide 12: Market Opportunity in Neurodegenerative Disease

    Market Opportunity in Neurodegenerative Disease NKGen’s SNK01, not yet approved by the U.S. Food and Drug Administration (FDA), will seek to address a multi-billion/year market Over 55 million people Alzheimer’s Disease (AD) We are aware of no therapies worldwide had dementia in and Parkinson’s Dise

  13. Slide 13: Autoreactive T cells Cause Neuroinflammation And Damage

    Autoreactive T cells Cause Neuroinflammation And Damage Chronic protein deposition leads to an autoinflammatory cascade and damage Removing proteins only addresses one aspect of the underlying pathology Activation of Autoreactive CD4+ and CD8+ T cells1-5 which migrate to the brain via CXCR36 1. Lind

  14. Slide 14: Autoreactive T cells And SNK01 Cross BBB Via CXCR3

    Autoreactive T cells And SNK01 Cross BBB Via CXCR3 SNK01 Has High CXCR3 Expression And Strong Migration Potential CXCR3 Expression CXCR3+ T cells migrate to CXCL10 positive astrocytes that frequently are associated with amyloid deposits.1 CXCR3 was highly expressed on a subpopulation of neurons and

  15. Slide 15: NK Cells Regulate Autoreactive T cells

    NK Cells Regulate Autoreactive T cells1-4 SNK01 Has Enhanced NKG2D and DNAM-1 Expression that helps identify and eliminate autoreactive T-cells and auto-immune neuroinflammation DNAM-1 M Tube_007 P1 5 UL UR 10 0.49 99.40 4 10 CD56 3 10 FITC A 2 10 LL LR 0 2 0.03 0.08 -10 -10 2 0 10 2 10 3 10 4 10 5

  16. Slide 16: Effects of Activated T-cells on Cytokines, Cytotoxic Activity, and IFN-γ in SNK01

    Effects of Activated T-cells on Immunosuppressive Cytokines, Cytotoxic Activity, and IFN-γ Expression in SNK01 Cells Level of Immunosuppressive cytokines in conditioned media of SNK01 cells The production of IL-10 (A) and TGF-β1 (B) by SNK01 cells for 2 days cultivation after stimulation with or wit

  17. Slide 17: SNK01 Can Reduce Amyloid, p-Tau, Alpha-Synuclein, and Neuroinflammation

    SNK01 Can Reduce Amyloid, p-Tau, Alpha-Synuclein, and Neuroinflammation NK cells have been found to prevent and reduce protein accumulation1,2 NK cells have also been found to identify and degenerate intact sensory axons after nerve injury3 1. Earls - PNAS - January 2020 117 (3) 1762-1771. 2. Marsh

  18. Slide 18: Functional Characteristics of SNK01 Cells for AD

    Functional Characteristics of SNK01 Cells for AD Uptake and degradation of aggregated amyloid-beta (Aβ) proteins (A-E) Intracellular levels of Aβ aggregates in SNK01 and HMC3 cells were analyzed by Western blot analysis. (A) SNK01 cells were treated with varying concentrations of Aβ aggregates for 1

  19. Slide 19: Uptake and degradation of aggregated α-synuclein proteins

    Uptake and degradation of aggregated α-synuclein proteins (A-E) Intracellular levels of α-syn aggregates in SNK01 and HMC3 cells were analyzed by Western blot analysis. (A) SNK01 cells were treated with varying concentrations of α-syn aggregates for 1 hour and harvested. (B) SNK01 cells were treated

  20. Slide 20: Neurodegenerative Scientific Advisory Board

    Neurodegenerative Scientific Advisory Board Craig Blackstone, M.D., Ph.D. Ming Guo, M.D., Ph.D. Anthony T. Reder, M.D. • Chief of Movement Disorders Division • P. Gene & Elaine Smith Chair in  Professor of Neurology at at Massachusetts General Hospital Alzheimer’s Disease Research, UCLA UChicago Me

  21. Slide 21: Case Studies

    Case Studies 21

  22. Slide 22: Compassionate Case Study #1 - 38 Y.O. With PSEN1 Mutation And Advanced Alzheimer's

    Compassionate Case Study # 1 - 38 Y.O. With PSEN1 Mutation And Advanced Alzheimer’s Treated With SNK01 IMPRESSION: Striking decreased parietal activity with moderate diffuse temporal, occipital and posterior fossa activity. RESULTS AND INTERPRETATIONS: This patient is heterozygous in the PSEN1 gene

  23. Slide 23: Alzheimer's Compassionate Use Case Study #2 - 70 Y.O.

    Alzheimer’s Compassionate Use Case Study # 2 70 Y.O With Advanced Alzheimer's Treated With SNK01 Clinical response after six treatments (July 2020 – December 2020). Patient had noticeable improvement in her overall cognitive function. But treatment was stopped for 2 years due to Covid. THESE REPORTS

  24. Slide 24: Compassionate Use Case Study #2 – 70 Y.O. With Advanced Alzheimer's

    Compassionate Use Case Study # 2 – 70 Y.O. With Advanced Alzheimer’s Treated With SNK01 Technical Results: Aβ42 369.1 pg/ml Patient was originally diagnosed in 2016 at Columbia University Medical Center with Advanced Alzheimer’s Disease. T-Tau 692.6 pg/ml P-Tau 83.5 pg/ml ATI 0.35 Patient received 6

  25. Slide 25: Patient Was Granted Single Compassionate Use IND Approval By US FDA

    Patient Was Granted Single Compassionate Use IND Approval By US FDA To Resume SNK01 Treatment Patient resumed treatment on 1/27/2023 and has had 3 monthly doses to date at the Neurologic Associates of Long Island Clinic under the care of Dr. Vincent DeOrchis. Currently plan to treat indefinitely unt

  26. Slide 26: 2024 Clinical Milestones Timeline

    2024 Clinical Milestones Timeline Phase I Dose Limiting Toxicity (“DLT”) Assessment Phase IIa 3-Month Interim Data AAIC Annual Meeting AAIC Abstract Submission Phase IIa begins Phase I/IIa IND Submission FDA Phase I/IIa IND Clearance Phase I Combination with Immune Checkpoint ASCO Annual Meeting Inh

  27. Slide 27: Phase I Data

    [DD ws. national Lisrary of Medicine =a Find Studles + About Studios ¥ Submit Studies ¥ Resources ¥ About Shey PRS Login ClinicalTrials.gov Search Results Save this study Safety of SNKO1 in Subjects With Alzheimer's Disease (ASK-AD) (ASK-AD) ‘Ginicarrrals gov Identiner: NCTO4678453 The safety and sc

  28. Slide 28: Biomarker Data From MX04 Phase I Trial

    Biomarker Data From MX04 Phase I Trial No observed serious adverse events (SAEs) or dose limiting toxicity Improvements seen in Aβ42/40, p-Tau, and alpha-synuclein protein levels Reductions seen in neuroinflammation markers: GFAP, NfL, YKL-40 SNK01’s ability to reduce all proteins and neuroinflammat

  29. Slide 29: Inflammatory and Neuronal Damage Markers (CSF) Data From MX04 Phase I Trial

    Inflammatory and Neuronal Damage Markers (CSF) Data From MX04 Phase I Trial 29

  30. Slide 30: Changes In Cognitive Function Post SNK01 Treatment

    Changes In Cognitive Function Post SNK01 Treatment Data From MX04 Phase I Trial Cognitive assessments at week 22 (12 weeks post last dose) Week 22 - All Patients compared to week 11; By dose cohort 10 9 CDR-SB ADAS-Cog MMSE 8 7 10 No. of patients 9 6 8 No. of patients 5 7 6 4 5 3 4 2 3 2 1 1 0 0 CDR

  31. Slide 31: Alzheimer's Disease Composite Score (ADCOMS)

    Alzheimer’s Disease Composite Score (“ADCOMS”) A composite of the Clinical Dementia SNK01 Alzheimer’s Phase I Trial Rating (CDR) scale in its ‘sum of boxes’ incarnation (CDR-sb),with the addition of four memory ADAS-cog (Delayed Word Recall, Orientation, Word Finding Difficulty & Word Recognition),

  32. Slide 32: SNK01 Phase I/2a Trial in AD

    SNK01 Phase I/2a Trial in AD Randomized Phase II trial launched August 2024 32

  33. Slide 33: Initial SNK01 Data from Phase 1 Trial in Alzheimer's

    Initial SNK01 Data from Phase 1 Trial in Alzheimer’s First three patients enrolled at 6 x 109 Dosing CDR-SB Analysis Timepoint Subject 1 Subject 2 Subject 3 Baseline 9.5 (Moderate) 12 (Moderate) 11 (Moderate) Week 14 (3 months) 7.5 (Mild) 12 (Moderate) 7 (Mild) Week 26 (6 months 7.5 (Mild) n/a n/a 0

  34. Slide 34: SNK01 has been shown to reduce each of these biomarkers

    SNK01 has been shown to reduce each of these biomarkers Suggesting SNK01 as a possible preventative treatment GFAP NfL GDF-15 Ltbp2 p-Tau 181 NfL GFAP 34

  35. Slide 35: NKGen Announces FDA Clearance of IND for SNK01 in Parkinson's Disease

    *W.NKGEN NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNKO1 NK Cell Therapy in Parkinson's Disease Published: Apr 29, 2024 NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNKO1 Clinical Trial in patients with P

  36. Slide 36: Thank you

    Thank you

  37. Slide 37: Intellectual Property

    Intellectual Property NK Cell Expansion Platform Patents Patent Family 1 Patent Family 2 • Highly cytotoxic NK Cells • Larger yields -- ideal for allogeneic production • Consistently large yields (including unhealthy • Even stronger cytotoxicity donors) • Method patent granted in the U.S. • Granted

  38. Slide 38: References For Neurodegenerative Disease

    References For Neurodegenerative Disease • Zhou, Y-Q, et al. (2019). The role of CXCR3 in Neurological Diseases. Curr Neuropharmacol, 17(2): 142-150. • Marsh, S.E., et al. (2016). The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function. Proc Natl Acad

  39. Slide 39: References Neurodegenerative Disease (Cont.)

    References Neurodegenerative Disease (Cont.) • Earls, R.H., et al., (2020). NK cells clear alpha-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of alpha- synucleinopathy. Proc Natl Acad Sci U S A, 117(3):1762-1771. • Rabinovich, B.A., et al. (2003). Activate

NKGen Biotech — Investor Presentation (September 2024) on 6ix